HOME >> MEDICINE >> NEWS
Zengen reports positive phase I/II trial results of its peptide molecule for vaginal yeast infection

(May 25, 2004) Zengen Inc. announced today positive phase I/II results for its proprietary molecule CZEN-002 for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection. The open label, non-randomized study was designed to evaluate the safety, tolerability and pharmacokinetics of CZEN-002 in patients with VVC.

The majority of subjects in the study reported evidence of efficacy as determined by potassium hydroxide (KOH) tests and mycological cultures - 88.2 percent and 87.5 percent, respectively. A total of 20 female patients with VVC were enrolled and treated in the trial, and 17 completed the study. KOH testing and mycological cultures indicated that CZEN-002 is active and that five days of treatment provided positive evidence of anti-infective efficacy. CZEN-002 appeared safe and well-tolerated with no severe adverse reactions. In 100 percent of the plasma samples evaluated, concentrations of CZEN 002 were either not detected or were below the limit of quantitation.

"This trial clearly established the efficacy of CZEN-002," said William Smith, M.D., F.A.C.C., lead study investigator and associate professor, clinical medicine, at Tulane University School of Medicine and Louisiana State University Medical Center. "The encouraging results provide hope that this compound may become a new treatment option for the millions of women diagnosed each year with VVC."

The primary objective of the study was to evaluate the safety and tolerability of vaginally administered CZEN-002. A secondary objective was to assess the systemic absorption of CZEN-002 as determined by the plasma concentrations of the molecule through 21 days following dosing. The CZEN 002 was delivered to the 20 patients in a vaginal gel specifically designed for the purpose of the study.

"This clinical trial marks a major milestone for Zengen," said James M. Lipton, Ph.D., chief scientific officer of Zengen. "Our peptide appears to
'"/>

Contact: Cattaliya Snider
sniderc@ruderfinn.com
310-479-9929
Zengen
25-May-2004


Page: 1 2 3

Related medicine news :

1. Zengens new study reviews novel approach to control inflammation using melanocortin receptors
2. Lead in the environment causes violent crime, reports University of Pittsburgh researcher at AAAS
3. Study reports women dont experience undue pain, anxiety during mammography screening
4. Risks from labor after prior cesarean delivery low, study reports
5. Federal forum reports Americans aging well, but gaps remain
6. Early reports of thrombosis after insertion of drug-eluting stents
7. Study reports genetic susceptibility to alcoholism in NMDA receptor
8. Parents can provide accurate reports of their childrens ADHD symptoms
9. UCI Tobacco research center reports why teens are most vulnerable to smoking addiction
10. MIT reports new insights in visual recognition
11. Study reports improved method to identify fetal DNA in maternal blood samples

Post Your Comments:
(Date:7/7/2015)... ... ... Law Group is pleased to announce the relocation of the firm's headquarters to 225 ... a state of the art building, located with easy access to New York City's ... "We are pleased to service our clients from such a premier location and we ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... SC&H Group, ... Service, which aims to give back to the community through company-wide volunteering efforts. , ... SC&H Group dedicate the day to assisting those in need throughout Baltimore and Washington ...
(Date:7/7/2015)... ... , ... At the end of June Pacific Prime Renewals team in Hong Kong announced ... by the Renewals Manager, Danielle Cotton, aims to not only reduce but eventually eliminate the ... explained, “We send anything between 300 and 600 pieces of paper per month. Not to ...
(Date:7/7/2015)... ... 07, 2015 , ... Summer is a great time to get outside and ... sharing some safety tips. , Jean Tapley, senior wellness coordinator at Amica, suggests the ... , Start slowly. Going from no activity to several hours of activity ...
(Date:7/7/2015)... ... ... Healthpointe is proud to announce the addition of Dr. Pedro S. Alupay to ... evaluating and treating patients with orthopedic complaints, such as lumbar back pain or cervical ... Biology from the University of the East, Manila, Dr. Alupay earned his Doctorate of ...
Breaking Medicine News(10 mins):Health News:SC&H Group Celebrates 9th Annual Day of Service 2Health News:Pacific Prime Hong Kong Renewals Team Starts Push to go Green 2Health News:Amica Insurance Has 7 Summer Safety Tips 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 3
(Date:7/7/2015)... 30, 2015 Research ... of the "Deciphering Global Major Pharmaceutical Companies, ... their offering. It has been publicly ... involved in a series of challenges in the ... in significant overcapacities in small molecule product manufacturing; ...
(Date:7/7/2015)...   Decision Resources Group finds that ... management in the U.S. versus the EU5. In ... EU5 nephrologists from approximately 1,870 dialysis patient charts ... commonly used renal medications in dialysis patients; however, ... the two regions.      Other key findings ...
(Date:7/7/2015)... California and BANGALORE , ... , a global technology provider of innovative clinical trial ... Reports, (Industry Standard Research Reports) recent publication named " ... Provider Performance (2015) ". ISR Reports is one of ... pharmaceutical industry, and this report evaluated 22 EDC and ...
Breaking Medicine Technology:Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 2Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 3Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 2Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 3
Cached News: